کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
1920438 1048695 2015 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease
ترجمه فارسی عنوان
آزمایشگاه خلبان تصادفی شده کنترل شدید سوپ فاز سولفناسین سوکسینات برای پروستات فوق فعال در بیماری پارکینسون
کلمات کلیدی
بیماری پارکینسون، مثانه بسیار فعال بی اختیاری ادرار، سولفناسین سوکسینات، علائم غیر حرکتی
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی سالمندی
چکیده انگلیسی


• Urinary dysfunction is a common non-motor feature in PD that significantly impacts patient quality of life.
• This double-blind, pilot trial evaluated the efficacy of solifenacin succinate in idiopathic PD patients with OAB.
• Twenty-three patients were randomized to treatment for 12 weeks followed by 8-weeks of open label extension.
• The mean number of urinary incontinence episodes per 24 h period decreased significantly in the solifenacin group.
• The open label phase found reductions in the mean number of urinary incontinence episodes and the number of nocturia episodes.

ObjectiveTo evaluate the efficacy of solifenacin succinate in Parkinson's disease (PD) patients suffering from overactive bladder (OAB).BackgroundUrinary dysfunction is a commonly encountered non-motor feature in PD that significantly impacts patient quality of life.Design/methodsThis was a double-blind, randomized, placebo-controlled, 3-site study with an open label extension phase to determine the efficacy of solifenacin succinate in idiopathic PD patients with OAB. Patients were randomized to receive solifenacin succinate 5–10 mg daily or placebo for 12 weeks followed by an 8-week open label extension. The primary outcome measure was the change in the mean number of micturitions per 24 h period. Secondary outcome measures included the change in the mean number of urinary incontinence episodes and the mean number of nocturia episodes.ResultsTwenty-three patients were randomized in the study. There was no significant improvement in the primary outcome measure in the double-blind phase, but there was an improvement in the number of micturitions per 24 h period in the solifenacin succinate group compared to placebo at a mean dose of 6 mg/day (p = 0.01). In the open label phase, the mean number of urinary incontinence episodes per 24 h period decreased (p = 0.03), as did the number of nocturia episodes per 24 h period (p = 0.01). Adverse events included constipation and xerostomia, which resolved after treatment was discontinued.ConclusionsIn this pilot trial, solifenacin succinate treatment led to an improvement in urinary incontinence, despite persistence in other OAB symptoms.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Parkinsonism & Related Disorders - Volume 21, Issue 5, May 2015, Pages 514–520
نویسندگان
, , , , , , , , ,